Insulin-Like Growth Factor 1 (IGF-1) – Test Update

This will take effect November 18, 2013

Overview and Clinical Utility:

Effective November 18, 2013, PathGroup will implement in-house testing for Insulin-Like Growth Factor (IGF-1). IGF-1, also known as somatomedin C, is a 70 amino acid polypeptide produced primarily by the liver in response to endocrine growth hormone (GH) stimulus. Although partially responsible for systemic GH activities, it additionally contributes to anabolic, antioxidant, and cytoprotective functions.

Click Here to read more.